Ciro Abbondanza

List of Publications by Year in descending order

48 papers	2,296 citations	304743 22 h-index	233421 45 g-index
48 all docs	48 docs citations	48 times ranked	3392 citing authors

#	Article	IF	Citations
1	Towards an Ideal In Cell Hybridization-Based Strategy to Discover Protein Interactomes of Selected RNA Molecules. International Journal of Molecular Sciences, 2022, 23, 942.	4.1	0
2	Does Gut-breast Microbiota Axis Orchestrates Cancer Progression?. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 1111-1122.	1.2	5
3	PRDM12 in Health and Diseases. International Journal of Molecular Sciences, 2021, 22, 12030.	4.1	5
4	Multifaceted Role of PRDM Proteins in Human Cancer. International Journal of Molecular Sciences, 2020, 21, 2648.	4.1	35
5	Searching for a Putative Mechanism of RIZ2 Tumor-Promoting Function in Cancer Models. Frontiers in Oncology, 2020, 10, 583533.	2.8	4
6	Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells. Frontiers in Pharmacology, 2019, 10, 28.	3.5	28
7	PR/SET Domain Family and Cancer: Novel Insights from the Cancer Genome Atlas. International Journal of Molecular Sciences, 2018, 19, 3250.	4.1	29
8	c-Myc Modulation and Acetylation Is a Key HDAC Inhibitor Target in Cancer. Clinical Cancer Research, 2017, 23, 2542-2555.	7.0	105
9	Pan-Cancer Mutational and Transcriptional Analysis of the Integrator Complex. International Journal of Molecular Sciences, 2017, 18, 936.	4.1	41
10	Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget, 2016, 7, 193-208.	1.8	91
11	HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. Oncotarget, 2015, 6, 886-901.	1.8	27
12	Telaprevir may induce adverse cutaneous reactions by a T cell immune-mediated mechanism. Annals of Hepatology, 2015, 14, 420-4.	1.5	4
13	Clinical Features of a New Acid-Labile Subunit <i>(IGFALS)</i> Heterozygous Mutation: Anthropometric and Biochemical Characterization and Response to Growth Hormone Administration. Hormone Research in Paediatrics, 2014, 81, 67-72.	1.8	17
14	Mouse Monoclonal Antibodies Against Estrogen Receptor. Methods in Molecular Biology, 2014, 1204, 165-185.	0.9	0
15	Retinoic acid impairs estrogen signaling in breast cancer cells by interfering with activation of LSD1 via PKA. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2013, 1829, 480-486.	1.9	22
16	PRDM Proteins: Molecular Mechanisms in Signal Transduction and Transcriptional Regulation. Biology, 2013, 2, 107-141.	2.8	58
17	Decreased serum vascular endothelial growth factorâ€Ð levels in metastatic patients with differentiated thyroid carcinoma. Clinical Endocrinology, 2012, 76, 142-146.	2.4	16
18	Identification of a functional estrogenâ€responsive enhancer element in the promoter 2 of PRDM2 gene in breast cancer cell lines. Journal of Cellular Physiology, 2012, 227, 964-975.	4.1	22

#	Article	IF	Citations
19	Highlighting chromosome loops in DNA-picked chromatin (DPC). Epigenetics, 2011, 6, 979-986.	2.7	9
20	Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework. Future Cardiology, 2011, 7, 485-497.	1.2	43
21	Expression of RIZ1 protein (Retinoblastomaâ€interacting zincâ€finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2. Journal of Cellular Physiology, 2009, 221, 771-777.	4.1	22
22	Differential expression of cyclooxygenases in hypertrophic scar and keloid tissues. Wound Repair and Regeneration, 2009, 17, 750-757.	3.0	21
23	DNA Oxidation as Triggered by H3K9me2 Demethylation Drives Estrogen-Induced Gene Expression. Science, 2008, 319, 202-206.	12.6	469
24	Detrimental effects of Bartonella henselae are counteracted by <scp>l</scp> -arginine and nitric oxide in human endothelial progenitor cells. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9427-9432.	7.1	29
25	Therapeutic targeting of the stem cell niche in experimental hindlimb ischemia. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 571-579.	3.3	33
26	Silencing of YY1 Downregulates RIZ1 Promoter in Human Osteosarcoma. Oncology Research, 2008, 17, 33-41.	1.5	14
27	Modulation of RIZ gene expression is associated to estradiol control of MCF-7 breast cancer cell proliferation. Experimental Cell Research, 2006, 312, 340-349.	2.6	35
28	Proteomic Analysis of MCF-7 Cell Lines Expressing the Zinc-Finger or the Proline-Rich Domain of Retinoblastoma-Interacting-Zinc-Finger Protein. Journal of Proteome Research, 2006, 5, 1176-1185.	3.7	19
29	The Zn-finger domain of RIZ protein promotes MCF-7 cell proliferation. Cancer Letters, 2004, 215, 229-237.	7.2	12
30	17Î²-estradiol-induced activation of ERK1/2 through endogenous androgen receptor-estradiol receptor Î±-Src complex in human prostate cells. International Journal of Oncology, 2003, 23, 797.	3.3	2
31	Differentiation of Myeloid Cell Lines Correlates with a Selective Expression of RIZ Protein. Molecular Medicine, 2001, 7, 552-560.	4.4	10
32	Detection of the M_r 110,000 Lung Resistance-related Protein LRP/MVP with Monoclonal Antibodies. Journal of Histochemistry and Cytochemistry, 2001, 49, 1379-1385.	2.5	10
33	Loss of Estrogen Receptor Î² Expression in Malignant Human Prostate Cells in Primary Cultures and in Prostate Cancer Tissues1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2051-2055.	3.6	80
34	Î³1- and Î³2-Syntrophins, Two Novel Dystrophin-binding Proteins Localized in Neuronal Cells. Journal of Biological Chemistry, 2000, 275, 15851-15860.	3.4	117
35	17Î²-Estradiol Inhibits Apoptosis in MCF-7 Cells, Inducing bcl-2 Expression via Two Estrogen-Responsive Elements Present in the Coding Sequence. Molecular and Cellular Biology, 2000, 20, 2890-2901.	2.3	317
36	Identification of a DNA Binding Protein Cooperating with Estrogen Receptor as RIZ (Retinoblastoma) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 983-989.	2.1	31

#	Article	IF	Citations
37	Interaction of Vault Particles with Estrogen Receptor in the MCF-7 Breast Cancer Cell. Journal of Cell Biology, 1998, 141, 1301-1310.	5.2	93
38	Identification of the Syrian hamster cardiomyopathy gene. Human Molecular Genetics, 1997, 6, 601-607.	2.9	253
39	A 67 kDa non-hormone binding estradiol receptor is present in human mammary cancers. , 1996, 65, 574-583.		11
40	A novel p53 mutant in human breast cancer revealed by multiple SSCP analysis. Cancer Letters, 1994, 79, 73-75.	7.2	2
41	Characterization and epitope mapping of a new panel of monoclonal antibodies to estradiol receptor. Steroids, 1993, 58, 4-12.	1.8	56
42	Purified estrogen receptor enhances in vitro transcription. Biochemical and Biophysical Research Communications, 1992, 186, 803-810.	2.1	5
43	Proteolytic activity of the purified hormone-binding subunit in the estrogen receptor.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 4463-4467.	7.1	8
44	In VitroBinding of the Purified Hormone-Binding Subunit of the Estrogen Receptor to Oligonucleotides Containing Natural or Modified Sequences of an Estrogen-Responsive Element. Molecular Endocrinology, 1991, 5, 555-563.	3.7	22
45	An aprotinin binding site localized in the hormone binding domain of the estrogen receptor from calf uterus. Biochemical and Biophysical Research Communications, 1990, 170, 930-936.	2.1	5
46	Metal binding sites of the estradiol receptor from calf uterus and their possible role in the regulation of receptor function. Biochemistry, 1989, 28, 212-219.	2.5	22
47	Aprotinin inhibits the hormone binding of the estrogen receptor from calf uterus. Biochemical and Biophysical Research Communications, 1989, 164, 1206-1211.	2.1	3
48	Estradiol receptor has proteolytic activity that is responsible for its own transformation.. Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 5367-5371.	7.1	34